307 related articles for article (PubMed ID: 30314724)
1. Effect of lateral lymph node dissection for mid and low rectal cancer: An ad-hoc analysis of the ACTS-RC (JFMC35-C1) randomized clinical trial.
Oki E; Shimokawa M; Ando K; Murata A; Takahashi T; Maeda K; Kusumoto T; Munemoto Y; Nakanishi R; Nakashima Y; Saeki H; Maehara Y
Surgery; 2019 Mar; 165(3):586-592. PubMed ID: 30314724
[TBL] [Abstract][Full Text] [Related]
2. Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212): results from a multicentre, randomised controlled, non-inferiority trial.
Fujita S; Akasu T; Mizusawa J; Saito N; Kinugasa Y; Kanemitsu Y; Ohue M; Fujii S; Shiozawa M; Yamaguchi T; Moriya Y;
Lancet Oncol; 2012 Jun; 13(6):616-21. PubMed ID: 22591948
[TBL] [Abstract][Full Text] [Related]
3. Selective lateral lymph node dissection after neoadjuvant chemoradiotherapy in rectal cancer.
Chen JN; Liu Z; Wang ZJ; Mei SW; Shen HY; Li J; Pei W; Wang Z; Wang XS; Yu J; Liu Q
World J Gastroenterol; 2020 Jun; 26(21):2877-2888. PubMed ID: 32550762
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC).
Oki E; Murata A; Yoshida K; Maeda K; Ikejiri K; Munemoto Y; Sasaki K; Matsuda C; Kotake M; Suenaga T; Matsuda H; Emi Y; Kakeji Y; Baba H; Hamada C; Saji S; Maehara Y
Ann Oncol; 2016 Jul; 27(7):1266-72. PubMed ID: 27056996
[TBL] [Abstract][Full Text] [Related]
5. Lateral pelvic lymph node dissection after neoadjuvant chemo-radiation for preoperative enlarged lateral nodes in advanced low rectal cancer: study protocol for a randomized controlled trial.
Wei M; Wu Q; Fan C; Li Y; Chen X; Zhou Z; Han J; Wang Z
Trials; 2016 Nov; 17(1):561. PubMed ID: 27884204
[TBL] [Abstract][Full Text] [Related]
6. Laparoscopic Versus Open Lateral Lymph Node Dissection for Locally Advanced Low Rectal Cancer: A Subgroup Analysis of a Large Multicenter Cohort Study in Japan.
Yamaguchi T; Konishi T; Kinugasa Y; Yamamoto S; Akiyoshi T; Okamura R; Ito M; Nishimura Y; Shiozawa M; Yamaguchi S; Hida K; Sakai Y; Watanabe M
Dis Colon Rectum; 2017 Sep; 60(9):954-964. PubMed ID: 28796734
[TBL] [Abstract][Full Text] [Related]
7. Oncological outcomes of robotic-assisted laparoscopic versus open lateral lymph node dissection for locally advanced low rectal cancer.
Yamaguchi T; Kinugasa Y; Shiomi A; Kagawa H; Yamakawa Y; Furutani A; Manabe S; Yamaoka Y; Hino H
Surg Endosc; 2018 Nov; 32(11):4498-4505. PubMed ID: 29721748
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of survival and functional outcomes after total mesorectal excision with or without lateral pelvic lymph node dissection in rectal cancer surgery.
Hajibandeh S; Hajibandeh S; Matthews J; Palmer L; Maw A
Surgery; 2020 Sep; 168(3):486-496. PubMed ID: 32620303
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of Laparoscopic Total Mesorectal Excision with Extended Lateral Pelvic Lymph Node Dissection for Advanced Lower Rectal Cancer after Preoperative Chemoradiotherapy.
Ogura A; Akiyoshi T; Nagasaki T; Konishi T; Fujimoto Y; Nagayama S; Fukunaga Y; Ueno M; Kuroyanagi H
World J Surg; 2017 Mar; 41(3):868-875. PubMed ID: 27730352
[TBL] [Abstract][Full Text] [Related]
10. [Transanal lateral lymph node dissection surgery for 5 cases of mid-low rectal cancer].
Zeng ZW; Zhang XW; Chen JJ; Huang L; Luo SL; Kang L
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Aug; 22(8):781-785. PubMed ID: 31422618
[No Abstract] [Full Text] [Related]
11. Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stage.
Shin K; Park SJ; Lee J; Park CH; Song KY; Lee HH; Seo HS; Jung YJ; Park JM; Lee SH; Roh SY; Kim IH
BMC Cancer; 2019 Dec; 19(1):1232. PubMed ID: 31852475
[TBL] [Abstract][Full Text] [Related]
12. Potential impact of lateral lymph node dissection (LLND) for low rectal cancer on prognoses and local control: A comparison of 2 high-volume centers in Japan that employ different policies concerning LLND.
Kanemitsu Y; Komori K; Shida D; Ochiai H; Tsukamoto S; Kinoshita T; Moriya Y
Surgery; 2017 Aug; 162(2):303-314. PubMed ID: 28366499
[TBL] [Abstract][Full Text] [Related]
13. Lateral lymph node dissection for mid-to-low rectal cancer: is it safe and effective in a practice-based cohort?
Numata M; Tamagawa H; Kazama K; Kawahara S; Sawazaki S; Aoyama T; Maezawa Y; Kano K; Higuchi A; Godai T; Saigusa Y; Saeki H; Yukawa N; Rino Y
BMC Surg; 2021 Jan; 21(1):51. PubMed ID: 33478441
[TBL] [Abstract][Full Text] [Related]
14. Monthly tegafur-uracil maintenance for increasing relapse-free survival in ypStage III rectal cancer patients after preoperative radiotherapy, radical resection, and 12 postoperative chemotherapy cycles: a retrospective study.
Kuo YH; Lai CH; Huang CY; Chen CJ; Huang YC; Huang WS; Chin CC
BMC Cancer; 2019 Aug; 19(1):815. PubMed ID: 31419963
[TBL] [Abstract][Full Text] [Related]
15. Mesorectal Excision With or Without Lateral Lymph Node Dissection for Clinical Stage II/III Lower Rectal Cancer (JCOG0212): A Multicenter, Randomized Controlled, Noninferiority Trial.
Fujita S; Mizusawa J; Kanemitsu Y; Ito M; Kinugasa Y; Komori K; Ohue M; Ota M; Akazai Y; Shiozawa M; Yamaguchi T; Bandou H; Katsumata K; Murata K; Akagi Y; Takiguchi N; Saida Y; Nakamura K; Fukuda H; Akasu T; Moriya Y;
Ann Surg; 2017 Aug; 266(2):201-207. PubMed ID: 28288057
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy with uracil-tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: a multicenter randomized controlled trial.
Akasu T; Moriya Y; Ohashi Y; Yoshida S; Shirao K; Kodaira S;
Jpn J Clin Oncol; 2006 Apr; 36(4):237-44. PubMed ID: 16675478
[TBL] [Abstract][Full Text] [Related]
17. Predictive factors of pathological lateral pelvic lymph node metastasis in patients without clinical lateral pelvic lymph node metastasis (clinical stage II/III): The analysis of data from the clinical trial (JCOG0212).
Komori K; Fujita S; Mizusawa J; Kanemitsu Y; Ito M; Shiomi A; Ohue M; Ota M; Akazai Y; Shiozawa M; Yamaguchi T; Bandou H; Katsumata K; Kinugasa Y; Takii Y; Akasu T; Moriya Y;
Eur J Surg Oncol; 2019 Mar; 45(3):336-340. PubMed ID: 30477950
[TBL] [Abstract][Full Text] [Related]
18. Local recurrences in western low rectal cancer patients treated with or without lateral lymph node dissection after neoadjuvant (chemo)radiotherapy: An international multi-centre comparative study.
Kroon HM; Malakorn S; Dudi-Venkata NN; Bedrikovetski S; Liu J; Kenyon-Smith T; Bednarski BK; Ogura A; van de Velde CJH; Rutten HJT; Beets GL; Thomas ML; Kusters M; Chang GJ; Sammour T
Eur J Surg Oncol; 2021 Sep; 47(9):2441-2449. PubMed ID: 34120810
[TBL] [Abstract][Full Text] [Related]
19. Recurrence of rectal cancer on the pelvic sidewall after lateral lymph node dissection.
Takao M; Kawai K; Nakano D; Dejima A; Nakamori S; Natsume S; Ise I; Kato H; Yamaguchi T
Int J Colorectal Dis; 2024 May; 39(1):80. PubMed ID: 38806953
[TBL] [Abstract][Full Text] [Related]
20. The Prognostic Significance of Isolated Tumor Cells Detected Within Lateral Lymph Nodes in Rectal Cancer Patients After Laparoscopic Lateral Lymph Node Dissection.
Yang X; Hu T; Gu C; Yang S; Jiang D; Deng X; Wang Z; Zhou Z
J Laparoendosc Adv Surg Tech A; 2019 Nov; 29(11):1462-1468. PubMed ID: 31539301
[No Abstract] [Full Text] [Related]
[Next] [New Search]
